Market closed
RxSight/$RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
498
Website
RxSight Metrics
BasicAdvanced
$1B
-
-$0.71
1.18
-
Price and volume
Market cap
$1B
Beta
1.18
52-week high
$66.54
52-week low
$24.64
Average daily volume
575K
Financial strength
Current ratio
11.355
Quick ratio
10.329
Long term debt to equity
4.026
Total debt to equity
4.372
Interest coverage (TTM)
-1,755.14%
Management effectiveness
Return on assets (TTM)
-9.19%
Return on equity (TTM)
-12.43%
Valuation
Price to revenue (TTM)
7.005
Price to book
3.63
Price to tangible book (TTM)
3.63
Price to free cash flow (TTM)
-43.788
Growth
Revenue change (TTM)
57.09%
Earnings per share change (TTM)
-49.93%
3-year revenue growth (CAGR)
83.64%
3-year earnings per share growth (CAGR)
-41.75%
What the Analysts think about RxSight
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
RxSight Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RxSight Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RxSight News
AllArticlesVideos
RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance
GlobeNewsWire·2 weeks ago
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $1B as of March 15, 2025.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of March 15, 2025.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of March 15, 2025.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.